This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): venlafaxine XR, Ifekusa [JP]
Description: Effexor XR is formulated as an extended-release capsule for once-a-day oral administration. The active ingredient of Effexor, venlafaxine hydrochloride, is a structurally novel antidepressant for oral administration. Effexor is a potent inhibitor of norepinephrine and serotonin reuptake, the two neurotransmitters that are thought to play important roles in the pathophysiology of depression.
Deal Structure: Effexor XR was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.
Effexor XR News
Pink Sheet Wyeth-Ayerst Effexor, Effexor XR
Pink Sheet In Brief: Wyeth-Ayerst Effexor XR
Additional information available to subscribers only: